Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

ESC and EASD organize Joint Scientific Forum in China to address optimal treatment strategies for diabetes

As a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), two of the most respected professional medical organisations in Europe, will be held from 27-29 November at three venues across China - Beijing, Shanghai and Guangzhou.

21 Nov 2009

FDA approves sNDA for pediatric autism drug ABILIFY

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.

20 Nov 2009

POZEN commences enrollment in PA32540 phase 3 study

POZEN Inc. announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.

20 Nov 2009

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

New education strategies for better controlling hypertension and research suggesting a possible link between short-term and long-term exposure to air pollution and increased risk of constricted blood vessels are among the research highlights from studies supported by the National Heart, Lung, and Blood Institute (NHLBI) at the American Heart Association's 2009 Scientific Sessions in Orlando held Nov. 14-18.

20 Nov 2009

High blood pressure: A major risk factor for stroke and heart disease

Today, Jamieson Laboratories, in partnership with the Victorian Order of Nurses (VON), is holding a one day Blood Pressure Blitz in Toronto's underground PATH system in an effort to educate consumers about the number one risk factor for stroke and a major risk factor of heart disease.

20 Nov 2009

Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients

Sleep apnea is common in individuals who receive a kidney transplant and is associated with increased risk of high blood pressure, heart disease or stroke, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

20 Nov 2009

Toddlers and obese children suffer more than youth when exposed to secondhand smoke

Toddlers and obese children suffer more than other youth when exposed to secondhand smoke, according to research presented at the American Heart Association's Scientific Sessions 2009.

19 Nov 2009

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.

19 Nov 2009

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

Pfizer Canada accepted the Prix Galien Canada 2009 Innovative Product Award for CHAMPIX (varenicline tartrate), the first prescription treatment for smoking cessation in adults specifically designed to target nicotine addiction. The award was presented last night at a gala in Ottawa recognizing excellence in pharmaceutical research.

18 Nov 2009

Phase 2/3 study results of Genzyme's APB announced

Genzyme Corporation today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela® (sevelamer carbonate).

18 Nov 2009

KAI Pharmaceuticals to receive manufacturing services from Formatech

Today, Formatech announced that they have selected KAI Pharmaceuticals, Inc. and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program.

18 Nov 2009

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib.

18 Nov 2009

Ambrisentan improves health and exercise capacity of PAH patients, find researchers

In one of the few studies of the long-term effects of medication in the treatment of pulmonary arterial hypertension (PAH) disease, a team of researchers found the health and exercise capacity of PAH patients improved after two years of treatment with ambrisentan, according to a study published in the current edition of the Journal of the American College of Cardiology.

18 Nov 2009

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

IBM (IBM) scientists have created a one-step point-of-care-diagnostic test, based on an innovative silicon chip, that requires less sample volume, is significantly faster, portable, easy to use, and can test for many diseases, including one of world's leading causes of death, cardiovascular disease.

18 Nov 2009

CRESTOR reduces major cardiovascular events in women by 46%

A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.

18 Nov 2009

Pediatric data for Pfizer's Lipitor submitted to the EMEA

Pfizer Inc announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission.

18 Nov 2009

Data demonstrate that danger of low levels of HDL is not reduced by statin treatment

Data released today at the American Heart Association (AHA) Scientific Sessions 2009 define the increased risk of heart attacks and cardiovascular disease in patients with low levels of HDL-C (known as "good cholesterol"). The data also determine that statins are unable to significantly impact the heart attack or cardiovascular disease risks associated with low HDL-C.

18 Nov 2009

Transcendental Meditation may be effective in reducing BP and psychological distress

"The Transcendental Meditation Program, a widely-used standardized program to reduce stress, showed significant decreases in blood pressure and improved mental health in young adults at risk for hypertension," said David Haaga, PhD, co-author of the study and professor of psychology at American University in Washington, D.C.

18 Nov 2009

Combination of night work, overtime and shortened sleep can increase risk of stroke and heart disease

A new study published in the current issue of Archives of Environmental & Occupational Health (vol. 64, No. 3) shows that this combination of night work, overtime and shortened sleep can contribute to the development among police officers of the metabolic syndrome, a combination of unhealthful factors that increase the risk of cardiovascular disease (CVD), primarily heart disease and stroke.

18 Nov 2009

First gene expression test for coronary artery disease

The Heart & Vascular Center of Arizona today announced the availability of Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(i) coronary artery disease (CAD) in patients with stable chest pain.

18 Nov 2009

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

ESC and EASD organize Joint Scientific Forum in China to address optimal treatment strategies for diabetes

FDA approves sNDA for pediatric autism drug ABILIFY

POZEN commences enrollment in PA32540 phase 3 study

NHLBI-supported research shares new strategies on hypertension, heart defect and air pollution

High blood pressure: A major risk factor for stroke and heart disease

Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients

Toddlers and obese children suffer more than youth when exposed to secondhand smoke

Results from Phase IIa clinical trial evaluating VT-111 reported by Viron Therapeutics

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

Phase 2/3 study results of Genzyme's APB announced

KAI Pharmaceuticals to receive manufacturing services from Formatech

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

Ambrisentan improves health and exercise capacity of PAH patients, find researchers

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

CRESTOR reduces major cardiovascular events in women by 46%

Pediatric data for Pfizer's Lipitor submitted to the EMEA

Data demonstrate that danger of low levels of HDL is not reduced by statin treatment

Transcendental Meditation may be effective in reducing BP and psychological distress

Combination of night work, overtime and shortened sleep can increase risk of stroke and heart disease

First gene expression test for coronary artery disease

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in